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ABSTRACT
Objectives: To assess variation in and determinants of
rheumatologist guideline adherence in patients with
rheumatoid arthritis (RA), in daily practice.
Methods: In this retrospective observational study,
guideline adherence in the first year of treatment was
assessed for 7 predefined parameters on diagnostics,
treatment and follow-up in all adult patients with RA
with a first outpatient clinic visit at the study centre,
from September 2009 to March 2011. Variation in
guideline adherence was assessed on parameter and
rheumatologist level. Determinants for guideline
adherence were assessed in patients (demographic
characteristics, rheumatoid factor (RF) and/or anti-cyclic
citrullinated peptide antibody (aCCP) positivity,
erythrocyte sedimentation rate, erosive disease,
comorbidity and the number of available disease
modifying anti-rheumatic drug (DMARD) treatment
options) and rheumatologists (demographic and
practice characteristics, guideline knowledge and
agreement, outcome expectancy, cognitive bias,
thinking style, numeracy and personality).
Results: A total of 994 visits in 137 patients with RA
were reviewed. Variation in guideline adherence among
parameters was present (adherence between 21% and
72%), with referral to the physician assistant as lowest
scoring and referral to a specialised nurse as highest
scoring parameter. Variation in guideline adherence
among rheumatologists was also present (adherence
between 22% and 100%). Patient sex, the number of
DMARD options, presence of erosions, comorbidity, RF/
aCCP positivity, type of patient and the rheumatologists’
scientific education status were associated with
adherence to 1 or more guideline parameters.
Conclusions: Guideline adherence varied considerably
among the guideline parameters and rheumatologists,
showing that there is room for improvement. Guideline
adherence in our sample was related to several patient
and rheumatologist determinants.
INTRODUCTION
Many guidelines and recommendations on
optimal care for patients with rheumatoid
arthritis (RA) have been developed to help
clinicians choose the best diagnostic and thera-
peutic strategies for their patients with RA. All
major RA treatment guidelines are now based
on tight control principles, where monitoring
of disease activity and changing treatment if a
preset target is not reached are essential.1–3
Adherence to these tight control principles,
preferably combined with the use of a speciﬁc
treatment guideline, results in lower disease
activity and less functional damage compared
with usual care.4–6
Key messages
What is already known about this subject?
▸ Guideline adherence to tight control treatment
strategies is often suboptimal when assessed in
predefined rheumatoid arthritis (RA) cohorts.
What does this study add?
▸ This is one of the first studies to assess RA
guideline adherence by rheumatologists in daily
practice, and to explore associations between
guideline adherence, and patient-related and
rheumatologist-related determinants.
▸ Previous studies on RA guideline adherence
focused on therapy change and/or disease modi-
fying anti-rheumatic drug prescriptions, whereas
we now included a broader range of parameters
covering diagnostics, treatment and follow-up.
▸ In this study, adherence percentages varied consid-
erably among the 7 parameters (range: 21–72%)
and 14 rheumatologists (range: 22–100%), with
several patient-related and rheumatologist-related
determinants explaining part of the inter-
rheumatologist variation.
How might this impact on clinical practice?
▸ The results of this study can serve as a stepping
stone for further research into effective interven-
tions to improve rheumatologists’ guideline
adherence, allowing patients to benefit from
optimal RA care.
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In view of the evidence supporting the beneﬁt of
adhering to tight protocolised control strategies, it is
disappointing that current guideline adherence is still
suboptimal, as observed in multiple studies on this
topic.7–13 Unfortunately, these studies focus on disease
modifying anti-rheumatic drug (DMARD)-related treat-
ment recommendations only, disregarding the fact that
other aspects of RA care are also important.
Furthermore, these studies are not performed in daily
practice, but in predeﬁned cohorts, using subsets of
patients with RA. Therefore, the ﬁrst aim of this study is
to gain more insight into guideline adherence of rheu-
matologists in daily practice, using a broader set of
guideline adherence parameters than before.
Our second study aim is to gain insight into determi-
nants of guideline adherence. In order to improve
guideline adherence, it is ﬁrst necessary to understand
the determinants that inﬂuence adherence. Knowledge
on these determinants could then be used to develop
targeted interventions, as evidence suggests that this
leads to better intervention effects.14 Although knowl-
edge on determinants of guideline adherence is not yet
available from studies within rheumatology, studies
outside rheumatology suggest the importance of various
determinants, explaining the observed variation in
guideline adherence among both, hospitals and physi-
cians.15 Examples of such determinants are knowledge
and cognitions of individual healthcare professionals
and patient factors.15
All in all, data on RA guideline adherence in daily
routine and its association with potential determinants
are still lacking. Therefore, we aimed to (1) assess RA
guideline adherence in daily clinical practice, (2) assess
variation in guideline adherence on parameter and
rheumatologist level and (3) explore the impact of
rheumatologist-related and patient-related determinants
on guideline adherence.
MATERIAL AND METHODS
Study design
An explorative, retrospective observational multilevel
cohort study was performed. Guideline adherence is
behaviour executed by a rheumatologist, but it is mea-
sured in patients who visit the hospital. Hence this study
has three different levels: outpatient clinic visits (level 1)
are nested within patients (level 2) who are in turn
nested within rheumatologists (level 3). This is also
reﬂected in the data collection and measurement: guide-
line adherence is measured on patient or visit level
(data collection on visit level), whereas the possible
determinants of guideline adherence were measured
either on rheumatologist or patient level.
Setting
This study was conducted at the Rheumatology
Department of the Sint Maartenskliniek, a large clinic
in the Netherlands, specialised in rheumatology,
rehabilitation medicine and orthopaedics. In this centre,
a local, tight control-based, RA treatment guideline was
initially put into use in 2007. At the same time, support-
ive actions were undertaken to aid rheumatologists in
following the new guideline. First, specialised nurses
were available to provide patient education, discuss
disease coping and to assess disease activity before the
visit with the rheumatologist (nurse-led assessment of
the Disease Activity Score in 28 joints (DAS28)).
Second, after a referral to the physician assistant (PA) by
the rheumatologist, patients were seen in alternating
fashion by the PA and rheumatologist in order to share
care between the two. The PAs can independently make
treatment decisions but they work under the supervision
of a rheumatologist and, at the time of this study, were
not allowed to prescribe medication.
Participants
All 14 rheumatologists working at the study centre from
September 2009 through July 2012 were eligible for par-
ticipation. Rheumatologists who did not work the full
period were excluded; no other exclusion criteria were
set. Consent from all participants was sought while
explaining the study during a regular staff meeting.
We included all patients 18 years of age and older,
diagnosed with RA (International Classiﬁcation of
Diseases, Ninth Revision (ICD-9) code 714.0), treated by
one of the included rheumatologists and having had a
ﬁrst outpatient clinic visit at the study centre anytime
from September 2009 to March 2011. Patients with
either new or established RA were included, as long as
their ﬁrst visit to the study centre took place during the
given time period. If patients were seen as second opi-
nions they were only included if treatment was fully
taken over by the study centre. After inclusion, all visits
in the ﬁrst year of treatment at the study clinic were
used to assess guideline adherence (ﬁgure 1). This
means that the follow-up period lasted until March 2012.
Guideline adherence measures and data collection
As guideline adherence is multidimensional and cannot
be expressed by a single outcome measure, we deﬁned a
set of seven different parameters to measure various
quality aspects of RA care. These parameters are based
on the quality indicators stated in the Dutch national
RA treatment guideline.16 As the local RA guideline
used in the study centre is an adapted version of the
Dutch national guideline, the selected parameters were
adapted accordingly. This resulted in a set of seven
guideline adherence parameters concerning three main
Figure 1 Study timeframe. *This included start of data
collection and informing rheumatologists at the study centre
about this study.
2 Lesuis N, et al. RMD Open 2016;2:e000195. doi:10.1136/rmdopen-2015-000195
RMD Open
group.bmj.com on June 19, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
themes (diagnostics, treatment, follow-up and shared
care). All parameters are reported as dichotomous out-
comes (‘yes’ or ‘no’) but, depending on the type of par-
ameter, this is carried out either at visit or at patient
level. All guideline adherence parameters are described
in table 1. Online supplement 1 provides a more exten-
sive version of this table, including corresponding treat-
ment recommendations.
As mentioned before, all parameters were measured
during the ﬁrst year of treatment at the study centre. So,
after a patient was included (from September 2009 to
March 2011) all visits in the next year were used to
measure guideline adherence.
To calculate the different parameters, the following data
from every visit in the ﬁrst year of treatment were col-
lected: date and type of visit, name of treating rheumatolo-
gist, presence of a nurse-led DAS28 assessment, DAS28
score (using erythrocyte sedimentation rate (ESR)), func-
tional status by Health Assessment Questionnaire (HAQ),
clinical judgement of disease activity, radiographs ordered,
current medication use (conventional and biological
DMARD, glucocorticoids and/or non-steroidal anti-
inﬂammatory drugs (NSAIDs)), referral to a specialised
nurse and referral to a PA. Using predeﬁned algorithms,
the seven guideline parameters were calculated using the
aforementioned data.
Determinants of guideline adherence and data collection
Determinants of guideline adherence were assessed on
two different levels: patient and rheumatologist. On the
patient level, eight determinants were collected at base-
line: age, gender, type of patient (new or second
opinion), rheumatoid factor (RF) and/or anti-cyclic
citrullinated peptide antibody (aCCP) positivity, ESR,
presence of erosive disease, relevant comorbidity and
the number of available DMARD treatment options. The
last determinant provides the number of conventional
and biological DMARDs that patients have not yet used,
but could be prescribed in the future in case of treat-
ment failure on the current DMARD.
On the rheumatologist level, information on ﬁve
demographic and practice determinants was collected
(age, gender, PhD, years of work experience as a
rheumatologist and percentage of direct patient contact
per week at the outpatient clinic). Furthermore, all par-
ticipating rheumatologists were asked to complete self-
developed questionnaires on guideline knowledge and
agreement, and outcome expectancy. In addition, exist-
ing and validated questionnaires on cognitive bias, think-
ing styles, numeracy and personality traits were
administered.17–20 Some of the included questionnaires
expressed their score on ≥1 subscale, resulting in 14
determinants being calculated from seven question-
naires (table 2 and online supplement 2). All question-
naires, of which the invitation to participate was sent to
the rheumatologists in July 2012, were web-based. After
2 weeks, reminders were sent to all rheumatologists who
had not yet completed the questionnaires.
Data sources
All data needed to calculate the guideline adherence
parameters were retrospectively retrieved from paper
hospital charts, using paper case report forms and a
patient list generated from the administrative hospital
database. During this chart review, the patient-related
determinants were also collected. After chart review, all
data were entered into an electronic database and anon-
ymised. All rheumatologist-related determinants were
collected using the questionnaires mentioned in the pre-
vious section and scores were also entered into an elec-
tronic database. For the purpose of the study,
anonymising the rheumatologist data was not possible.
Statistical analysis
Results on primary outcome measures (guideline adher-
ence parameters) are reported as percentages with the
accompanying absolute numbers. For the questionnaire
scores and remaining variables, means and SD or
medians and IQRs are provided.
Table 1 Guideline adherence parameters
Guideline adherence parameter
Level of
measurement
Radiographs of hands, feet and thorax ordered within the first 3 visits, in patients with a disease
duration ≤1 year
Patients
Prescription of conventional and biological DMARDs in agreement with the local preferential
sequence
Patients
Referral to a specialised nurse within the first 3 visits Patients
Referral to a PA or NP within the first year of treatment Patients
Therapy change* in case of moderate-to-high disease activity† Visits
Regular outpatient clinic visits combined with a nurse-led DAS28 assessment Visits
Correct intervals between regular outpatient clinic visits Visits
*Therapy change included the intensification of DMARD therapy (dosage increase, shortening of the interval, adding a new DMARD and/or
biological, switching to another DMARD and/or biological), starting or increasing corticosteroids (dose), local corticosteroid injections.
†DAS28>3.2 or corresponding judgement from the rheumatologist if a DAS28 was not available.
DAS28, Disease Activity Score in 28 joints; DMARD, disease modifying anti-rheumatic drug; NP, nurse practitioner; PA, physician assistant.
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Owing to the hierarchical structure of our study
(repeated measures on the same patient and patient
nested within rheumatologists) we performed linear or
logistic multilevel regression analysis when analysing the
relation between the guideline adherence parameters
and determinants. Depending on the type of parameter
(outcomes on patient or visit level), two or three levels
were included in the analyses. For the parameters—radio-
graphs ordered, preferential DMARD order, referral to a
specialised nurse and referral to a PA (patient level)—
each parameter had the same score for every visit within
one patient. For example, patients should be referred to
a PA within the ﬁrst year of treatment, meaning that this
parameter is scored only once per patient, taking into
account all visits during the study period. Multilevel ana-
lysis for these parameters only accounted for clustering
within rheumatologists (two-level model). For the other
parameters (therapy change, nurse-led DAS28 assess-
ments and correct visit intervals; visit level) multilevel
analysis also accounted for clustering within patients.
This extra level was added because the parameter score
per visit could differ within patients. For example,
nurse-led DAS28 assessments were either conducted or
not conducted during the various visits.
Multilevel analysis started with adding all patient deter-
minants to the model. Then, one by one, the least signiﬁ-
cant determinant was deleted from the model until all
remaining determinants were signiﬁcant (p<0.05). Next,
the rheumatologist determinant with the highest correl-
ation was added to the multilevel regression model and,
if signiﬁcant, included in the ﬁnal regression model. This
process was repeated with the rheumatologist determin-
ant with the second highest correlation. Depending on
the p value of this determinant in the model, the analysis
was either stopped (ﬁnal model) or another determinant
was added. This method was chosen because the number
of rheumatologists was relatively small compared with the
number of rheumatologist-related determinants.
Only parameters and determinants with enough vari-
ation among rheumatologists were analysed for associa-
tions between them. In case of ﬂoor or ceiling effects, a
determinant was omitted from further analysis. Results
are presented as ORs with the corresponding 95% CI,
p value and explained variation (%). Explained vari-
ation was calculated using the method described by
Snijders and Bosker.21
Statistical analyses were performed using STATAV.13.0,
except the multilevel analysis, this was carried out using
SAS V.9.2.
Ethical approval
This study was approved by the local research committee
at the study centre (RR-105-PP). Although no written
informed consent was obtained from the rheumatolo-
gists, they were informed beforehand about this study
and asked if they would participate. It was made clear to
them that they could withdraw from the study at any
time, without providing a reason.
As this was a quality assessment performed in the hos-
pital where the ﬁrst two authors of this study worked, no
written informed consent was needed from the patients.
In addition, data collection was made by the ﬁrst author
and, directly after chart review, all patient data were
anonymised.
RESULTS
Rheumatologist and patient characteristics
All 14 eligible rheumatologists (46.2% female; mean age
47.6±10.0 years) participated in this study. All question-
naires were returned by all rheumatologists, except
for the questionnaires on guideline knowledge, and
Table 2 Questionnaires used to measure rheumatologist-level determinants
Determinant Questionnaire Number of scales Score range
Cognitive bias Inventory for Cognitive
Bias in Medicine (ICBM)17
1 0–22 (higher scores indicating less
cognitive bias)
Personality Big Five Inventory (BFI;
Dutch version)19
5 (extraversion, neuroticism,
openness, conscientiousness and
agreeableness)
1–5 on every subscale (higher scores
indicating a stronger personality trait on
the specific subscale)
Thinking styles Rational Experiential
Inventory (REI; Dutch
version)18
2 (rationality and experientality) 20–100 on every subscale (higher
scores indicating a more rational/
experiential thinking style)
Numeracy Berlin Numeracy Test
(BNT; Dutch version)20
1 0–7 (a higher score indicating a higher
level of numeracy)
Knowledge Self-developed
questionnaire
2 (general and specific knowledge) General knowledge: 0–10. Specific
knowledge: −5.2–10* (higher scores
indicating more guideline knowledge)
Guideline
agreement
Self-developed statements 2 (general and specific agreement
with the guideline)
1–5 on every subscale (a higher score
indicating a higher level of agreement)
Outcome
expectancy
Self-developed statement 1 1–5 (a higher score indicating a higher
level of outcome expectancy)
*Negative scores possible due to correction for guessing.
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agreement and outcome expectancy, which one rheuma-
tologist did not complete.
According to the hospital database, 241 patients with
an ICD-code of RA were seen for the ﬁrst time at the
study clinic, from September 2009 to March 2011.
Sixty-one patients were excluded because they turned out
to be second opinion patients of whom treatment was not
taken over by the study centre. Additionally, 43 patients
were excluded because either charts were missing (n=9),
patients were not seen by an included rheumatologist
(n=11), chart review revealed a diagnosis other than RA
(n=16) or patients had deceased (n=7). The remaining
137 patients with RA (67.2% female; mean age 58.9
±14.1 year), with a total of 994 visits, were included in this
study. Roughly half the patients had not been seen by a
rheumatologist before (46%); the remaining patients
had been treated before by a rheumatologist outside the
study centre, and visited the study centre for a second
opinion. This led to a combination of new and
established RA, as reﬂected in the median disease dur-
ation (0; IQR 0–7 years). In table 3, the baseline
characteristics of both, rheumatologists and patients, are
stated.
Guideline adherence parameters
Adherence to the different guideline adherence para-
meters varied between 21% and 72% (table 4). The best
scoring indicator was ‘referral to a specialised nurse’,
with 72% of the patients being referred to such a nurse.
Ordering of radiographs and changing therapy in case
of active disease was performed in approximately
two-thirds of patients or visits, respectively. The remain-
ing parameters had adherence percentages between
20% and 40% (PA referral, DMARD prescription, inter-
vals between visits and nurse-led DAS28 assessment).
As described in table 4, not all guideline parameters
apply to all patients or visits. For example, this applies to
the parameter ‘therapy change in case of active RA’.
A DAS28 and/or clinical judgment was available in 622
visits (63%) and, in 285 of these visits, active disease
(DAS28>3.2 or a corresponding judgement from the
treating rheumatologist) was present (46%). In 191 of
those visits (67%), the rheumatologists decided to
change the patient’s medication (parameter therapy
change in case of active disease).
In addition to the aforementioned variation among
guideline adherence parameters, variation was also
observed among rheumatologists. The largest difference
among rheumatologists was seen in the parameter con-
cerning radiograph ordering, with adherence percent-
age of individual rheumatologists varying from 22% to
100%. The least variation was seen in the parameter on
correct intervals between visits, with adherence percen-
tages varying from 11% to 43%.
Determinants of guideline adherence
All guideline adherence parameters showed enough
variation and no ﬂoor/ceiling effects were present,
therefore all parameters were included in the multilevel
analyses. However, ﬁve determinants (general guideline
knowledge, general guideline agreement, speciﬁc guide-
line agreement, outcome expectancy and numeracy)
were not included in the analyses due to lack of vari-
ation in the scores and/or ceiling effects (table 3).
For the remaining determinants, eight associations
with ﬁve different parameters were found (table 5). The
preferential order of DMARD prescriptions was adhered
less to in case of more available treatment options.
Furthermore, referral to a specialised nurse was less
likely if patients had erosive disease and comorbidity at
baseline. Females, aCCP-positive and/or RF-positive
patients and second opinions had less visits combined
Table 3 Baseline characteristics of included
rheumatologists and patients
Characteristic Results
Rheumatologists (n=14)
Age, in years* 45.2 (39.5 to 56.7)
Female gender (%) 46.2
PhD degree or pursuing a PhD (%) 69.2
Experience as rheumatologist, in
years*
6.9 (3.6 to 19.9)
Patient contact per week* (%) 60.0 (45.0 to 70.0)
Guideline knowledge† (0–10);
(−5.2 to 10)
General 8.1 (1.0)
Specific 6.2 (1.8)
Guideline agreement† (0–5)
General 4.8 (0.5)
Specific 4.5 (0.5)
Outcome expectancy† (0–5) 3.9 (0.8)
Cognitive bias† (0–22) 12.5 (4.2)
Thinking styles† (0–100)
Rational 79.5 (9.2)
Experiential 63.7 (7.5)
Numeracy† (0–7) 6.6 (1.1)
Personality† (0–5)
Extraversion 3.4 (0.7)
Neuroticism 2.8 (0.4)
Openness to experience 3.7 (0.6)
Consciousness 3.7 (0.4)
Agreeableness 3.8 (0.3)
Patients (n=137)
Age, in years† 58.9 (14.1)
Female gender (%) 67.2
Disease duration, in years* 0 (0 to 7)
RF and/or aCCP positive (%) 85.4
Erosions (%) 38.3
ESR* (mm/h) 25 (12 to 36)
Comorbidity (%) 66.4
Number of available DMARD
treatment options*‡
15 (14 to 15)
*Median (IQR).
†Mean (SD).
‡Includes both conventional and biological DMARD treatment
options.
aCCP, anti-cyclic citrullinated peptide antibody; DMARD, disease
modifying anti-rheumatic drug; ESR, erythrocyte sedimentation
rate; RF, rheumatoid factor.
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with a nurse-led DAS28 assessment. Correct intervals
between visits were also less likely if a patient was seen
for a second opinion.
Only one parameter was associated with a
rheumatologist-related determinant: rheumatologists
with a PhD degree or pursuing a PhD were more likely
to refer their patients to a PA. Personality, thinking styles
and cognitive bias did not impact rheumatologists’
adherence to any of the guideline adherence
parameters.
The explained variance of the models was low to mod-
erate. The lowest explained variance (2.5%) was seen in
the model on correct intervals between visits, and the
highest (12.0%) in the model on PA referral.
DISCUSSION
Our results show that guideline adherence percentages
varied considerably among parameters, suggesting sub-
optimal guideline adherence on at least some guideline
recommendations. Furthermore, adherence also varied
among rheumatologists, and several rheumatologist and
patient-related determinants (rheumatologists’ scientiﬁc
education status, patient sex, number of DMARD
options, presence of erosions, comorbidity, RF/aCCP
positivity, type of patient) were found to be related to
rheumatologists’ guideline adherence.
Besides being one of the ﬁrst studies in rheumatology
assessing guideline adherence in daily practice, other
strengths of this study are the inclusion of a wide range
of guideline adherence parameters, and the multilevel
association analyses between these parameters and deter-
minants. However, our study has some limitations. First,
being a retrospective study with chart review as the main
data source, it is possible that information has been
missed due to the fact that not everything was well docu-
mented in the charts. However, the advantage of our
retrospective design is that guideline adherence could
Table 5 Multivariate associations between guideline adherence parameters and P-related and R-related determinants
Guideline adherence parameter OR (95% CI) p Value
Prescription of DMARDs in agreement with the local preferential sequence
P Number of treatment options 0.78 (0.63 to 0.97) 0.03
Explained variance (%) 5.2
Referral to a specialised nurse within the first 3 visits
P Presence of erosive disease 0.68 (0.16 to 0.93) 0.03
P Comorbidity 0.68 (0.13 to 1.00) 0.05
Explained variance (%) 9.8
Referral to a PA or NP within the first year of treatment
R PhD degree or pursuing a PhD 4.14 (1.33 to 12.86) 0.01
Explained variance (%) 12.0
Regular outpatient clinic visits combined a nurse-led DAS28 assessment
P Female gender 0.63 (0.41 to 0.97) 0.04
P RF and/or aCCP positivity 0.43 (0.28 to 0.66) <0.01
P Seen by a R before (second opinion) 0.41 (0.22 to 0.77) 0.01
Explained variance (%) 7.9
Correct intervals between regular outpatient clinic visits
P Seen by a R before (second opinion) 0.56 (0.37 to 0.85) 0.01
Explained variance (%) 2.5
aCCP, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, disease modifying anti-rheumatic drug;
NP, nurse practitioner; P, patient; PA, physician assistant; R, rheumatologist; RF, rheumatoid factor.
Table 4 Guideline adherence percentages
Guideline adherence parameter
Adherence
percentage
Patient level (n=137)
Radiographs of hands, feet and
thorax ordered within the first 3
visits, in patients with a disease
duration ≤1 year
66 (53/80)
Prescription of DMARDs* in
agreement with the local preferential
sequence
23 (29/126)
Referral to a specialised nurse
within the first 3 visits
72 (98/137)
Referral to a PA or NP within the
first year of treatment
21 (29/137)
Visit level (n=994)
Therapy change† in case of
moderate-to-high disease activity
67 (191/285)
Regular outpatient clinic visits
combined a nurse led DAS28
assessment
37 (253/690)
Correct intervals between regular
outpatient clinic visits
32 (160/502)
*Conventional and biological DMARDs.
†Therapy change include starting or increasing dosage of a
conventional DMARD or oral corticosteroids, starting a biological
DMARD and intramuscular or intra-articular injections with
corticosteroids.
DAS28, Disease Activity Score in 28 joints; DMARD, disease
modifying anti-rheumatic drug; NP, nurse practitioner; PA,
physician assistant.
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not have been inﬂuenced by the study itself. Second, the
sample size was relatively small, with only 14 participat-
ing rheumatologists. Nonetheless, if we have missed asso-
ciations due to a lack of power, these associations are
probably not very strong. Third, this study was con-
ducted in only one centre in the Netherlands, probably
limiting generalisability. Nevertheless, our observation
that guideline adherence is suboptimal is most likely to
be generalisable, as earlier studies made the same con-
clusions. Only, our estimates on the degree of guideline
adherence might be less generalisable. Furthermore,
due to the single centre design, we were not able to
assess the inﬂuence of organisational factors on guide-
line adherence. As the study centre already implemen-
ted some supportive actions to increase adherence,
results in a centre without these actions might be differ-
ent. Last, the single-centre design and the homogeneous
population within this centre contributed to the exclu-
sion of some of our determinants due to ceiling effects
or lack of variation.
In our study, guideline adherence varied from 21% to
72% and, as no absolute norms on optimal guideline
adherence exist, we can only use relative norms to judge
if guideline adherence in this study was optimal. First,
the adherence percentages of our best scoring para-
meters can be used as a relative norm. So, the observed
level of adherence to the three highest scoring indica-
tors (radiograph ordering, specialised nurse referral,
therapy change; adherence 66–72%) was probably
optimal. Furthermore, aiming for 100% adherence is
not feasible due to, for example, patient comorbidity or
medication side effects.
Second, we can compare our results with other
studies. However, since previous studies have primarily
focused on therapy recommendations (DMARD pre-
scription and therapy change in case of active disease),
this makes comparison with existing data impossible for
all our parameters. With regard to DMARD prescrip-
tions, the 23% guideline adherence we found seems to
be on the lower end of the spectrum. Another study on
this subject observed adherence percentages to the
American College of Rheumatology (ACR) DMARD
treatment guidelines of 24% to 90%, depending on the
type of DMARD used, disease activity and prognosis.11
However, the lower adherence percentages in our study
could probably be explained by the more strict deﬁn-
ition we used. For example, the ACR guideline names
methotrexate as the ﬁrst choice DMARD, with combin-
ation therapy depending on disease activity, prognosis
and disease duration. In contrast, according to our local
guideline, all new patients should be started on metho-
trexate and hydroxychloroquine combination therapy.
With regard to therapy change in case of active
disease, we can compare our results with two previous
studies. A study by Fransen et al9 on patients with estab-
lished RA used the same DAS28 threshold (3.2) at
which therapy should be changed, as our study did,
observing an adherence percentage of 20%. Although
Fransen et al looked only at DMARD therapy change
whereas we included corticosteroid use as well, the
adherence of 67% that we found is substantially higher.
The result of the second study, by Vermeer et al,13 with
an adherence of 58%, is more in line with our results,
although it only included DMARD therapy change and
was limited to early RA. Concerning therapy change, it
should be mentioned that our centre has participated in
a guideline adherence study before. In that particular
study, therapy was changed in 33% of the visits with
active disease, compared to 67% now.22 This large
improvement in guideline adherence is most likely
caused by the introduction of the local RA guideline
and the supportive actions thereafter.
Besides the assessment of guideline adherence, we
also examined whether patient-related and
rheumatologist-related determinants were associated
with guideline adherence. On these associations some
interesting observations can be made. For example, in
qualitative studies, factors such as erosive disease,
comorbidity and RF/aCCP status, are often mentioned
by rheumatologists as important reasons to either inten-
sify or not intensify treatment.23 Therefore, we expected
to ﬁnd associations between these determinants and the
guideline parameter on therapy change in case of active
disease. Although we did not observe this association, we
observed associations between number of treatment
options, erosive disease, comorbidity and RF/aCCP
status, and the parameters on DMARD prescription,
referral to a specialised nurse and nurse-led DAS28
assessments. This implies that patient factors could,
justly or unjustly, inﬂuence more decisions than treat-
ment intensiﬁcation only.
With regard to the rheumatologist-related determi-
nants, it is notable that only one association between a
rheumatologist determinant (PhD) and a guideline
adherence parameter (PA referral) was found. This was
especially surprising as factors such as knowledge are
frequently mentioned as a potential determinant of
guideline adherence.15 24 This might imply that
rheumatologist-related determinants did not play a large
role in our sample, but further studies on this subject
are needed as guideline adherence is probably deter-
mined by a complex interplay of facilitators and barriers
that makes it hard to capture.
Owing to the explorative design of our study, replica-
tion of our results is warranted in other settings both
inside and outside the Netherlands. However, the sug-
gestion from our results that rheumatologists do not
always practise what they preach can be used more
widely. It seems that, despite the current focus on treat
to target principles in RA literature, these principles are
not automatically applied in daily practice.
This study provides an example for other centres to
measure their quality of care and the determinants
found in our sample might be reckoned with in future
interventions. Recent developments around nationwide
registries, such as the Rheumatology Informatics
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System for Effectiveness (RISE) registry, can facilitate
measurements by providing real-time feedback on
important aspects of quality of care.25 Information
gained from quality of care studies or registries can then
serve as benchmark information for hospitals and indi-
vidual physicians.26 Furthermore, we would advocate for
more attention of researchers and policymakers towards
implementation of RA guidelines and quality of care.
Besides replicating our results in larger studies, two
important topics for future research are the identiﬁca-
tion of determinants inﬂuencing adherence and explor-
ation of the impact of separate adherence parameters
on patient outcomes (eg, Does referral to a PA lead to
more patients being in remission?). Preferably, such
studies would be conducted in a large, nationwide multi-
centre setting in order to aid precision and generalisa-
tion of study results. These steps are crucial to gain
insight into the most effective and feasible interventions
to help rheumatologists better adhere to RA manage-
ment guidelines and to improve patient outcomes in
daily practice. Only then can patients beneﬁt from the
large body of evidence that already exists.
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